Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
By Albert Allotey Accra, Nov. 15, GNA – Some Civil Society Organisations (CSOs) have called for the urgent need to for a comprehensive approach to managing diabetes, ...